Current Month 2013
Article Features
  Aspirin Use Does Not Improve Outcomes for Cancer Patients, But May Lower Breast Density
Breast Cancer Detection Rate Using Ultrasound is Shown to be Comparable to Mammography
Breast Density Alone Found Not To Be A Factor for Breast Cancer Risk
Breast-Conserving Therapy Yielded Better Outcomes Than Mastectomy for Early-Stage Patients
Counseling With Genetic Cancer Screening May Increase Knowledge and Decrease Anxiety
DCIS Patients Receiving Anastrozole Reported Symptoms Different from Those Receiving Tamoxifen
Delaying Chemotherapy in Breast Cancer Patients Reduces Overall Survival, Especially For Those with Triple-Negative Breast Cancer
Drug Provides Another Treatment Option for an Early Form of Breast Cancer
Financial Burden of Cancer Survivorship Varies by Age, Cancer Site
Long-Term Outcomes of Preventing Premature Menopause During Chemotherapy
Mastectomy Plus Reconstruction Has Highest Rate of Complication, Complication-Related Costs of Guideline-Concordant Therapies for Early Breast Cancer
Mathematical Model Suggests Select DCIS Patients Could Delay Treatment
New Breast Cancer Drug May Be Effective Against Other Types of Cancer
New Research on Metastasis Illuminates How Cancer Cells Hijack Healthy Cells
New Study Identifies Method for Detecting Latent Stage of Lymphedema
Novel Imaging-Based Method for Defining Appropriateness of Breast Cancer Treatment
Periodontal Disease Associated with Increased Breast Cancer Risk in Postmenopausal Women
Simple Blood Test Could Help Tailor Treatments for Advanced Breast Cancer Patients
Study Examines Obesity in Relation to Breast Cancer Related Lymphedema
T Cells That Recognize HER2 Receptor May Prevent HER2+ Breast Cancer Recurrence
T-DM1 Improved Overall Survival for Heavily Pretreated Patients with HER2-Positive Breast Cancer
Travel Distance is Still a Barrier to Breast Reconstruction After Mastectomy
Uncovering Potentially Concerning Variation in Cancer Screening Follow-Ups
Why Does Tamoxifen Work Better in Some Women?


Financial Burden of Cancer Survivorship Varies by Age, Cancer Site

Survivors of cancer pay thousands of dollars in excess medical expenditures every year, with the excess financial burden varying by age and cancer site, according to a new American Cancer Society study. The study, appearing in the Journal of the National Cancer Institute, says targeted efforts will be important to reduce the economic burden of cancer.

As a group, cancer survivors (estimated to number 14.5 million in the United States in 2014) face greater economic burden, including medical expenditures and productivity losses. But relatively little is known about whether that burden varies by cancer site compared to similar individuals without a cancer history.

Researchers led by Zhiyuan 'Jason' Zheng, PhD, senior health services researcher in the Surveillance and Health Services Research program at the American Cancer Society, used 2008 to 2012 Medical Expenditure Panel Survey data to measure excess economic burden attributable to the three most prevalent cancers. They calculated excess annual medical expenditures and productivity losses (employment disability, missed work days, and days stayed in bed) for colorectal (n = 540), female breast (n = 1568), and prostate (n = 1170) cancer survivors, and for those without a cancer history (n = 109,423). They stratified the data by cancer site and age (non-elderly: 18-64 years vs elderly: 65+ years), and controlled for age, sex, race/ethnicity, marital status, education, number of comorbidities, and geographic region.

Read More of the Main Article

 
Visit the Ezine


Visit the BreastCenter

Visit the Quality Corner
Avon Breast Cancer Crusade - AVON the company for women

  This website is supported in part by an unrestricted educational grant provided by Avon